Huh Y O, Keating M J, Saffer H L, Jilani I, Lerner S, Albitar M
Departments of Hematopathology and Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030-4009, USA.
Am J Clin Pathol. 2001 Sep;116(3):437-43. doi: 10.1309/438N-E0FH-A5PR-XCAC.
Differential expression of CD20 surface antigen in B-cell neoplasms at different sites is largely unknown. The number of CD20 antibodies bound per cell (CD20 ABC) in bone marrow (BM), peripheral blood (PB), and lymph node aspirate (LNA) samples from patients with B-cell chronic lymphocytic leukemia (B-CLL) or other B-cell disease was studied using quantitative flow cytometry. CD20 ABC differed significantly with the specimen type in B-CLL, being highest in PB (mean, 9,051) and lower in BM (mean, 4,067) and LNA (mean, 3,951). No difference in CD20 ABC between BM and PB samples was found in splenic lymphoma, mantle cell lymphoma, or follicular lymphoma. Also, we found a significant difference of CD20 ABC by type of disease: lowest in B-CLL; higher in splenic, follicular, and mantle cell lymphoma; and highest in hairy cell leukemia. The lower CD20 surface antigen levels in BM and LNA than in PB in B-CLL may have clinical relevance with regard to the efficacy of rituximab therapy.
B细胞肿瘤中不同部位CD20表面抗原的差异表达情况在很大程度上尚不清楚。我们使用定量流式细胞术研究了B细胞慢性淋巴细胞白血病（B-CLL）或其他B细胞疾病患者的骨髓（BM）、外周血（PB）和淋巴结穿刺液（LNA）样本中每个细胞结合的CD20抗体数量（CD20 ABC）。在B-CLL中，CD20 ABC因标本类型不同而有显著差异，在外周血中最高（平均值为9051），在骨髓中较低（平均值为4067），在淋巴结穿刺液中更低（平均值为3951）。在脾淋巴瘤、套细胞淋巴瘤或滤泡性淋巴瘤中，未发现骨髓和外周血样本之间的CD20 ABC有差异。此外，我们发现CD20 ABC因疾病类型不同而有显著差异：在B-CLL中最低；在脾淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤中较高；在毛细胞白血病中最高。B-CLL患者骨髓和淋巴结穿刺液中CD20表面抗原水平低于外周血，这可能与利妥昔单抗治疗的疗效具有临床相关性。
